Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Convertible Debt: 2016-2022

Historic Convertible Debt for Theravance Biopharma (TBPH) over the last 5 years, with Jun 2022 value amounting to $228.6 million.

  • Theravance Biopharma's Convertible Debt rose 0.47% to $228.6 million in Q2 2022 from the same period last year, while for Jun 2022 it was $228.6 million, marking a year-over-year increase of 0.47%. This contributed to the annual value of $228.0 million for FY2021, which is 0.47% up from last year.
  • Latest data reveals that Theravance Biopharma reported Convertible Debt of $228.6 million as of Q2 2022, which was up 0.12% from $228.3 million recorded in Q1 2022.
  • In the past 5 years, Theravance Biopharma's Convertible Debt registered a high of $228.6 million during Q2 2022, and its lowest value of $224.0 million during Q1 2018.
  • Its 3-year average for Convertible Debt is $227.4 million, with a median of $227.4 million in 2021.
  • Data for Theravance Biopharma's Convertible Debt shows a peak YoY grew of 0.48% (in 2018) over the last 5 years.
  • Over the past 5 years, Theravance Biopharma's Convertible Debt (Quarterly) stood at $224.8 million in 2018, then increased by 0.48% to $225.9 million in 2019, then increased by 0.48% to $227.0 million in 2020, then climbed by 0.47% to $228.0 million in 2021, then climbed by 0.47% to $228.6 million in 2022.
  • Its last three reported values are $228.6 million in Q2 2022, $228.3 million for Q1 2022, and $228.0 million during Q4 2021.